212 related articles for article (PubMed ID: 22585860)
1. The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer.
McKie AB; Vaughan S; Zanini E; Okon IS; Louis L; de Sousa C; Greene MI; Wang Q; Agarwal R; Shaposhnikov D; Wong JL; Gungor H; Janczar S; El-Bahrawy M; Lam EW; Chayen NE; Gabra H
Cancer Discov; 2012 Feb; 2(2):156-71. PubMed ID: 22585860
[TBL] [Abstract][Full Text] [Related]
2. New roles opined for OPCML.
Wu SY; Sood AK
Cancer Discov; 2012 Feb; 2(2):115-6. PubMed ID: 22585855
[TBL] [Abstract][Full Text] [Related]
3. The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.
Zanini E; Louis LS; Antony J; Karali E; Okon IS; McKie AB; Vaughan S; El-Bahrawy M; Stebbing J; Recchi C; Gabra H
Mol Cancer Ther; 2017 Oct; 16(10):2246-2256. PubMed ID: 28775148
[TBL] [Abstract][Full Text] [Related]
4. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer.
Sellar GC; Watt KP; Rabiasz GJ; Stronach EA; Li L; Miller EP; Massie CE; Miller J; Contreras-Moreira B; Scott D; Brown I; Williams AR; Bates PA; Smyth JF; Gabra H
Nat Genet; 2003 Jul; 34(3):337-43. PubMed ID: 12819783
[TBL] [Abstract][Full Text] [Related]
5. The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
Antony J; Zanini E; Kelly Z; Tan TZ; Karali E; Alomary M; Jung Y; Nixon K; Cunnea P; Fotopoulou C; Paterson A; Roy-Nawathe S; Mills GB; Huang RY; Thiery JP; Gabra H; Recchi C
EMBO Rep; 2018 Aug; 19(8):. PubMed ID: 29907679
[TBL] [Abstract][Full Text] [Related]
6. Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival.
Zhou F; Tao G; Chen X; Xie W; Liu M; Cao X
Clin Chem Lab Med; 2014 May; 52(5):735-42. PubMed ID: 24327526
[TBL] [Abstract][Full Text] [Related]
7. Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers.
Antony J; Zanini E; Birtley JR; Gabra H; Recchi C
Cancer Gene Ther; 2021 Feb; 28(1-2):18-26. PubMed ID: 32595215
[TBL] [Abstract][Full Text] [Related]
8. Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions.
Birtley JR; Alomary M; Zanini E; Antony J; Maben Z; Weaver GC; Von Arx C; Mura M; Marinho AT; Lu H; Morecroft EVN; Karali E; Chayen NE; Tate EW; Jurewicz M; Stern LJ; Recchi C; Gabra H
Nat Commun; 2019 Jul; 10(1):3134. PubMed ID: 31316070
[TBL] [Abstract][Full Text] [Related]
9. [*OPCML gene transferred by recombinant lentiviruses in vitro and its inhibition to ovarian cancer cells].
Yao DS; Li L; Garson K; Vanderhyden BC
Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):333-8. PubMed ID: 16762191
[TBL] [Abstract][Full Text] [Related]
10. Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.
Rea K; Pinciroli P; Sensi M; Alciato F; Bisaro B; Lozneanu L; Raspagliesi F; Centritto F; Cabodi S; Defilippi P; Avanzi GC; Canevari S; Tomassetti A
Oncotarget; 2015 Oct; 6(31):30859-75. PubMed ID: 26356564
[TBL] [Abstract][Full Text] [Related]
11. RAS-mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells.
Mei FC; Young TW; Liu J; Cheng X
FASEB J; 2006 Mar; 20(3):497-9. PubMed ID: 16384911
[TBL] [Abstract][Full Text] [Related]
12. Expression and promoter methylation status of OPCML and its functions in the inhibition of cell proliferation, migration, and invasion in breast cancer.
Lian B; Li H; Liu Y; Chai D; Gao Y; Zhang Y; Zhou J; Li J
Breast Cancer; 2021 Mar; 28(2):448-458. PubMed ID: 33108608
[TBL] [Abstract][Full Text] [Related]
13. Expression of ovarian tumour suppressor OPCML in the female CD-1 mouse reproductive tract.
Fleming JS; McQuillan HJ; Millier MJ; Sellar GC
Reproduction; 2009 Apr; 137(4):721-6. PubMed ID: 19176311
[TBL] [Abstract][Full Text] [Related]
14. Down-regulated expression of OPCML predicts an unfavorable prognosis and promotes disease progression in human gastric cancer.
Xing X; Cai W; Ma S; Wang Y; Shi H; Li M; Jiao J; Yang Y; Liu L; Zhang X; Chen M
BMC Cancer; 2017 Apr; 17(1):268. PubMed ID: 28407749
[TBL] [Abstract][Full Text] [Related]
15. LIM-homeobox transcription factor 1, alpha (LMX1A) inhibits tumourigenesis, epithelial-mesenchymal transition and stem-like properties of epithelial ovarian cancer.
Chao TK; Yo YT; Liao YP; Wang YC; Su PH; Huang TS; Lai HC
Gynecol Oncol; 2013 Mar; 128(3):475-82. PubMed ID: 23270808
[TBL] [Abstract][Full Text] [Related]
16. Cumulative methylation alternations of gene promoters and protein markers for diagnosis of epithelial ovarian cancer.
Xing BL; Li T; Tang ZH; Jiao L; Ge SM; Qiang X; OuYang J
Genet Mol Res; 2015 May; 14(2):4532-40. PubMed ID: 25966226
[TBL] [Abstract][Full Text] [Related]
17. [Effects of WWOX gene transfection on cell growth of epithelial ovarian cancer].
Yan HC; Xue JQ; Lu XY; Wan MR; Feng X; Liu XY
Zhonghua Fu Chan Ke Za Zhi; 2008 May; 43(5):361-5. PubMed ID: 18953870
[TBL] [Abstract][Full Text] [Related]
18. Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer.
Czekierdowski A; Czekierdowska S; Szymanski M; Wielgos M; Kaminski P; Kotarski J
Neuro Endocrinol Lett; 2006 Oct; 27(5):609-13. PubMed ID: 17159813
[TBL] [Abstract][Full Text] [Related]
19. OPCML: A Promising Biomarker and Therapeutic Avenue.
Simovic I; Castaño-Rodríguez N; Kaakoush NO
Trends Cancer; 2019 Aug; 5(8):463-466. PubMed ID: 31421903
[TBL] [Abstract][Full Text] [Related]
20. Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.
Wang ZQ; Bachvarova M; Morin C; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Bachvarov D
Oncotarget; 2014 Jan; 5(2):544-60. PubMed ID: 24504219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
